chr20-46726905-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_030777.4(SLC2A10):c.1330C>T(p.Arg444Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000062 in 1,614,006 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_030777.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC2A10 | NM_030777.4 | c.1330C>T | p.Arg444Ter | stop_gained | 3/5 | ENST00000359271.4 | NP_110404.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC2A10 | ENST00000359271.4 | c.1330C>T | p.Arg444Ter | stop_gained | 3/5 | 1 | NM_030777.4 | ENSP00000352216 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152138Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251470Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135914
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461868Hom.: 0 Cov.: 32 AF XY: 0.00000550 AC XY: 4AN XY: 727240
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152138Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74322
ClinVar
Submissions by phenotype
Arterial tortuosity syndrome Pathogenic:4Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 16, 2022 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 161101). This premature translational stop signal has been observed in individual(s) with arterial tortuosity syndrome (PMID: 17163528). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs370547023, gnomAD 0.004%). This sequence change creates a premature translational stop signal (p.Arg444*) in the SLC2A10 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC2A10 are known to be pathogenic (PMID: 17935213, 22488877, 23494979). - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 12, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 08, 2024 | Variant summary: SLC2A10 c.1330C>T (p.Arg444X) results in a premature termination codon, predicted to cause absence of the protein due to nonsense mediated decay, which is a commonly known mechanism for disease. The variant allele was found at a frequency of 4e-06 in 251470 control chromosomes (gnomAD). c.1330C>T has been reported in the literature in an individual affected with Arterial Tortuosity Syndrome (Drera_2007). Experimental evidence from fibroblasts from the patient reported in Drera, et al showed the genotype resulted in markedly reduced transport of DAA through endomembranes (Nemeth_2016) as well as absence of the typical patterns of GLUT10 perinuclear and mitochondrial decoration via immunostaining (Gamberucci_2017). The following publications have been ascertained in the context of this evaluation (PMID: 17163528, 28829359, 27153185). ClinVar contains an entry for this variant (Variation ID: 161101). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University Hospital Muenster | Feb 08, 2022 | ACMG categories: PVS1,PP3,PP5 - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 31, 2023 | The p.R444* pathogenic mutation (also known as c.1330C>T), located in coding exon 3 of the SLC2A10 gene, results from a C to T substitution at nucleotide position 1330. This changes the amino acid from an arginine to a stop codon within coding exon 3. This variant was has been detected in the compound heterozygous state with a second SLC2A10 alteration in an individual with arterial tortuosity syndrome (Drera B et al. Am J Med Genet A, 2007 Jan;143A:216-8). Functional studies have indicated this variant impacts protein function (Zoppi N et al. Hum Mol Genet, 2015 Dec;24:6769-87; Németh CE et al. FEBS Lett, 2016 Jun;590:1630-40). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 12, 2017 | The R444X variant in the SLC2A10 gene has been reported in an Italian patient who was compound heterozygous for theR444X nonsense variant and the E437K missense variant (Drera et al., 2007). Drera et al. (2007) describe a 14 year old child with clinical features of ATS including stenosis, and tortuosity of the left pulmonary artery, tortuosity of carotid, vertebral, and intracerebral arteries and a family history significant for two deceased siblings with findings suggestive of ATS. R444X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. Nemeth et al. (2016) performed in vivo studies from fibroblasts of the patient described by Drera et al. (2007) demonstrating the absence of mRNA due to nuclear mediated decay, with restoration of normal endomembrane transport of DAA when transfected with wild-type SCL10A2. Other nonsense variants in the SLC2A10 gene have been reported in Human Gene Mutation Database in association with ATS (Stenson et al., 2014). Furthermore, the R444X variant is not observed at asignificant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome VariantServer). In summary, although R444X in the SLC2A10 gene is interpreted as a likely pathogenic variant - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at